A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.
- 16 Apr 2018 Planned End Date changed from 30 Mar 2023 to 30 Jun 2023.
- 16 Apr 2018 Planned primary completion date changed from 30 Mar 2021 to 30 Jun 2021.